In contrast to CB42, CBP1 showed a non-significant trend toward mild tumor growth inhibition in response to the MEK-inhibitor, the CDK6-inhibitor, or the combination, reaching at most 45% TGI in the combination arm (Fig. 7A). The gene discussed is CDK6; the disease is neoplasm.